bluuebunny/crossref_metadata_2025_split huggingface dataset:
Shareholding Formulas in International Financial Institutions: Learning From the Asian Infrastructure Investment Bank
Authors: Gu Bin , Liu Tong 
Published: September 2022

ABSTRACT
Shareholding formulas determine member countries’ voice in capital-based international organizations. They are crucial for international finance and draw much attention in negotiations. In principle, these formulas reflect member countries’ relative economic positions, but in practice, they serve as a starting point in negotiations, alongside other economic and political factors. This article investigates the unique shareholding formula of the Asian Infrastructure Investment Bank (AIIB), and compares it with those of the Bretton Woods institutions, that is, the International Monetary Fund (IMF), the International Bank for Reconstruction and Development (IBRD), and the International Finance Corporation (IFC). It shows that both the AIIB and the Bretton Woods institutions have learnt from each other’s shareholding formulas. Built upon the Bretton Woods practice, the AIIB’s gross domestic product-based shareholding formula could stimulate the IMF to establish a new quota formula under the 16th general review of quotas, the IBRD to implement the results calculated from its 2016 Dynamic Formula, and the IFC to develop its own formula by the date of the next shareholding review in 2025.
Dripping with Blood and Dirt from Head to Toe: Marx’s Genealogy of Capitalism in Capital, Volume 1
Authors: Allen Amy 
Published: September 2022

Abstract
I argue that Marx’s critique of political economy in volume 1 of Capital relies on a kind of genealogical argument that takes capitalism as its object. In the first section of the article, I sketch out an interpretation of the argumentative structure of Capital 1, highlighting what I take to be the two crucial turning points in Marx’s critique of political economy. Marx’s specifically genealogical argument comes to the foreground with the second of these turning points, which can be found at the start of his account of primitive accumulation in Part 8 of Capital 1. The first part of the paper defends the thought that the genealogy of capitalism’s prehistory is no mere digression from or complement to the main theoretical argument, but rather the crucial completion of Marx’s critique of political economy in Capital 1. In the second part of the paper, I turn to the somewhat thornier question of what sort of genealogy Marx offers. Drawing on and extending Bernard Williams’s distinction between vindicatory and subversive genealogies, I contend that Marx’s genealogy of capitalism, despite containing both subversive and vindicatory strands, is embedded in a longer vindicatory historical arc that, while avoiding crude teleologies and strong claims to unilinearity, nonetheless maintains a kind of necessity claim for its genealogical object.
On Moral Unintelligibility: Beauvoir’s Genealogy of Morality in the Second Sex
Authors: Vaccarino Bremner Sabina 
Published: September 2022

Abstract
This paper offers a reading of Beauvoir’s Second Sex as a genealogy of ‘morality’: the patriarchal system of values that maintains a moral distinction between men and women. This value system construes many of women’s experiences under oppression as evidence of women’s immorality, obscuring the agential role of those who provoke such experiences. Beauvoir’s examination of the origin for this value system provides an important counterexample to the prevailing debate over whether genealogical method functions to debunk or to vindicate: while the currently dominant moral system may have been historically necessary at certain stages in human development, Beauvoir nevertheless debunks it; only the value system itself now remains, without its precipitating needs. Thus, Beauvoir’s critique reveals what I call the moral unintelligibility of women’s experiences of oppression: women encounter difficulty in making sense of the harms wrought against them because the operative value system obscures them as harms in the first place, instead construing women themselves as immoral. Against the prevailing construction of moral blame and responsibility, Beauvoir’s solution is the political virtue of moral invention, a virtue epistemic as well as moral, collective as well as individual.
Reason Versus Power: Genealogy, Critique, and Epistemic Injustice
Authors: Lorenzini Daniele 
Published: September 2022

AbstractIn this paper, I take issue with the idea that Michel Foucault might be considered a theorist of epistemic injustice, and argue that his philosophical premises are incompatible with Miranda Fricker’s. Their main disagreement rests upon their divergent ways of conceiving the relationship between reason and power, giving rise to the contrasting forms of normativity that characterize their critical projects. This disagreement can be helpfully clarified by addressing the different use they make of the genealogical method. While Fricker’s genealogy of Testimonial Justice aims to ground her claim that reason and power can be neatly pulled apart, thus avoiding the reductionist and relativist conclusions entailed (in her view) by Foucault’s genealogies, I argue that Foucault’s mature, overlooked definition of genealogy is based on a sophisticated distinction between games and regimes of truth, and is thus not vulnerable to these criticisms. Consequently, Foucault’s genealogical inquiries prove helpful for understanding issues that normally fall under the umbrella of epistemic injustice in a new light, while also allowing us to avoid some of the main objections that threaten Fricker’s project.
A toolkit for the identification of NEAT1_2/paraspeckle modulators
Authors: An Haiyan , Elvers Karen T , Gillespie Jason A , Jones Kimberley , Atack John R , Grubisha Olivera , Shelkovnikova Tatyana A 
Published: September 2022

Abstract
Paraspeckles are ribonucleoprotein granules assembled by NEAT1_2 lncRNA, an isoform of Nuclear Paraspeckle Assembly Transcript 1 (NEAT1). Dysregulation of NEAT1_2/paraspeckles has been linked to multiple human diseases making them an attractive drug target. However currently NEAT1_2/paraspeckle-focused translational research and drug discovery are hindered by a limited toolkit. To fill this gap, we developed and validated a set of tools for the identification of NEAT1_2 binders and modulators comprised of biochemical and cell-based assays. The NEAT1_2 triple helix stability element was utilized as the target in the biochemical assays, and the cellular assay (‘ParaQuant’) was based on high-content imaging of NEAT1_2 in fixed cells. As a proof of principle, these assays were used to screen a 1,200-compound FDA-approved drug library and a 170-compound kinase inhibitor library and to confirm the screening hits. The assays are simple to establish, use only commercially-available reagents and are scalable for higher throughput. In particular, ParaQuant is a cost-efficient assay suitable for any cells growing in adherent culture and amenable to multiplexing. Using ParaQuant, we identified dual PI3K/mTOR inhibitors as potent negative modulators of paraspeckles. The tools we describe herein should boost paraspeckle studies and help guide the search, validation and optimization of NEAT1_2/paraspeckle-targeted small molecules.
Impact of previous REnal TRansplantation on the mid-term renal Outcome after CARdiac surgery: the RETROCAR trial
Authors: Beurton Antoine , Fajardie Antoine , Rubin Sebastien , Belnou Pierre , Aguerreche Clement , Pernot Mathieu , Mion Stefano , Imbault Julien , Ouattara Alexandre 
Published: September 2022

ABSTRACT

Background
Acute kidney injury (AKI) is one of the most common complications after cardiac surgery with cardiopulmonary bypass (CPB). Renal transplant recipients (RTRs) have a higher risk of cardiac surgery–associated AKI (CSA-AKI). A relationship has been strongly suggested between AKI and poor long-term graft survival. The main objective was to evaluate the impact of on-pump cardiac surgery on the 1-year renal allograft survival rate.

Methods
The study population consisted of 37 RTRs and 56 non-RTRs who underwent cardiac surgery between 1 January 2010 and 31 December 2019. They were matched according to age, sex, preoperative glomerular function, diabetes and type of surgery. The primary composite outcome was renal survival, defined as patient survival without the requirement for permanent dialysis or new kidney transplantation at 1 year after surgery.

Results
The renal survival rate was significantly lower in the RTR group than in the non-RTR group [81% versus 96%; odds ratio 0.16 (95% confidence interval 0.03–0.82), P = .03]. The proportion of patients who returned to permanent dialysis was higher in the RTR group than in the non-RTR group (12% versus 0%; P = .02). The proportion of patients with severe AKI was also higher in the RTR group. At 1 year after surgery, serum creatinine level, glomerular filtration rate and all-cause mortality rates were comparable between both groups.

Conclusion
Patients with a functional renal allograft have a low 1-year renal allograft survival rate after cardiac surgery with CPB. In addition, these patients have significant risks of AKI and acute kidney disease after open-heart surgery.
Pregnancy, Parthood and Proper Overlap: A Critique of Kingma
Authors: Geddes Alexander 
Published: September 2022

AbstractElselijn Kingma argues that, in cases of mammalian placental pregnancy, the foster (roughly, the post-implantation embryo/foetus) is part of the gravida (the pregnant organism). But she does not consider the possibility of proper overlap. I show that this generates a number of serious problems for her argument and trace the oversight to a quite general issue within the literature on biological individuality. Doing so provides an opportunity to pull apart and clarify the relations between some importantly distinct questions concerning organismality and organismic parthood, and to identify the implications that this has for those who want to draw on this literature when making metaphysical or mereological arguments.
Do Investors Care about Impact?
Authors: Heeb Florian , Kölbel Julian F , Paetzold Falko , Zeisberger Stefan 
Published: September 2022

Abstract
We assess how investors’ willingness-to-pay (WTP) for sustainable investments responds to the social impact of those investments, using a framed field experiment. While investors have a substantial WTP for sustainable investments, they do not pay significantly more for more impact. This also holds for dedicated impact investors. When investors compare several sustainable investments, their WTP responds to relative, but not to absolute, levels of impact. Regardless of investments’ impact, investors experience positive emotions when choosing sustainable investments. Our findings suggest that the WTP for sustainable investments is primarily driven by an emotional, rather than a calculative, valuation of impact.
A-phase index: an alternative view for sleep stability analysis based on automatic detection of the A-phases from the cyclic alternating pattern
Authors: Mendonça Fábio , Mostafa Sheikh Shanawaz , Gupta Ankit , Arnardottir Erna Sif , Leppänen Timo , Morgado-Dias Fernando , Ravelo-García Antonio G 
Published: September 2022

Abstract

Study Objectives
Sleep stability can be studied by evaluating the cyclic alternating pattern (CAP) in electroencephalogram (EEG) signals. The present study presents a novel approach for assessing sleep stability, developing an index based on the CAP A-phase characteristics to display a sleep stability profile for a whole night’s sleep.

Methods
Two ensemble classifiers were developed to automatically score the signals, one for “A-phase” and the other for “non-rapid eye movement” estimation. Both were based on three one-dimension convolutional neural networks. Six different inputs were produced from the EEG signal to feed the ensembles’ classifiers. A proposed heuristic-oriented search algorithm individually tuned the classifiers’ structures. The outputs of the two ensembles were combined to estimate the A-phase index (API). The models can also assess the A-phase subtypes, their API, and the CAP cycles and rate.

Results
Four dataset variations were considered, examining healthy and sleep-disordered subjects. The A-phase average estimation’s accuracy, sensitivity, and specificity range was 82%–87%, 72%–80%, and 82%–88%, respectively. A similar performance was attained for the A-phase subtype’s assessments, with an accuracy range of 82%–88%. Furthermore, in the examined dataset’s variations, the API metric’s average error varied from 0.15 to 0.25 (with a median range of 0.11–0.24). These results were attained without manually removing wake or rapid eye movement periods, leading to a methodology suitable to produce a fully automatic CAP scoring algorithm.

Conclusions
Metrics based on API can be understood as a new view for CAP analysis, where the goal is to produce and examine a sleep stability profile.
Explaining the Adoption of Care Policies in Costa Rica and Uruguay: A Multiple Streams Approach
Authors: Leon-Espinoza Diana 
Published: September 2022

AbstractThis article aims to reveal how Costa Rica and Uruguay succeeded in adopting integrated care policies. By adapting the classic “multiple streams approach,” I analyze the processes leading to the adoption of two care policies in Costa Rica and Uruguay. The findings suggest that the key to understanding the adoption of care policies lies within the interplay between agents and contexts in different streams. Problems can be constructed as a top-down process by a women’s agency or as a bottom-up process from a feminist organization. Solutions can be designed in close-knit policy networks of technocrats/bureaucrats or in open policy networks of bureaucrats and civil society organizations. Care policies become prominent items on government agendas in the presence of programmatic political parties and high electoral competition settings that prioritize the issue to attract voters or consolidate support. The alignment of problems, solutions, and politics identify different pathways that lead to the adoption of care policies.
A Systematic Review and Meta-Analysis Evaluating Geographical Variation in Outcomes of Cancer Patients Treated in ICUs
Authors: Nazer Lama H. , Lopez-Olivo Maria A. , Brown Anne Rain , Cuenca John A. , Sirimaturos Michael , Habash Khader , AlQadheeb Nada , May Heather , Milano Victoria , Taylor Amy , Nates Joseph L. 
Published: September 2022

OBJECTIVES:
The reported mortality rates of cancer patients admitted to ICUs vary widely. In addition, there are no studies that examined the outcomes of critically ill cancer patients based on the geographical regions. Therefore, we aimed to evaluate the mortality rates among critically ill cancer patients and provide a comparison based on geography.

DATA SOURCES:
PubMed, EMBASE, and Web of Science.

STUDY SELECTION:
We included observational studies evaluating adult patients with cancer treated in ICUs. We excluded non-English studies, those with greater than 30% hematopoietic stem cell transplant or postsurgical patients, and those that evaluated a specific type of critical illness, stage of malignancy, or age group.

DATA EXTRACTION:
Two reviewers independently applied eligibility criteria, assessed quality, and extracted data. Studies were classified based on the continent in which they were conducted. Primary outcomes were ICU and hospital mortality. We pooled effect sizes by geographical region.

DATA SYNTHESIS:
Forty-six studies were included (n = 110,366). The overall quality of studies was moderate. Most of the published literature was from Europe (n = 22), followed by North America (n = 9), Asia (n = 8), South America (n = 5), and Oceania (n = 2). Pooled ICU mortality rate was 38% (95% CI, 33–43%); the lowest mortality rate was in Oceania (26%; 95% CI, 22–30%) and highest in Asia (51%; 95% CI, 44–57%). Pooled hospital mortality rate was 45% (95% CI, 41–49%), with the lowest in North America (37%; 95% CI, 31–43%) and highest in Asia (54%; 95% CI, 37–71%).

CONCLUSIONS:
More than half of cancer patients admitted to ICUs survived hospitalization. However, there was wide variability in the mortality rates, as well as the number of available studies among geographical regions. This variability suggests an opportunity to improve outcomes worldwide, through optimizing practice and research.
Modeling Approach with Therapeutic Drug Monitoring Data to Describe Time Course of Clozapine Exposure and Positive and Negative Syndrome Scale Scores
Authors: Park Sang-In , Kim Seoyoung , Kim Min-Gul , Lim Hyeong-Seok , Kim Euitae 
Published: September 2022

Objective:
The Positive and Negative Syndrome Scale (PANSS) is commonly used to assess the severity of the clinical symptoms of schizophrenia (SCZ). This study aimed to develop a pharmacokinetic (PK)/pharmacodynamic (PD) model based on therapeutic drug monitoring (TDM) data to characterize the relationship between clozapine exposure and the PANSS scores in patients with SCZ.

Methods:
TDM data for clozapine and PANSS scores from 45 patients with SCZ were included in this modeling analysis using NONMEM. Based on published data, intensive PK sampling data collected up to 12 hours postdose from 23 patients was incorporated into the PK data set to improve the fitting of absorption and disposition. For PD model development, the PANSS score was assessed at baseline, followed by 8 and 18 weeks after the initiation of clozapine dosing. Visual predictive check plots, the precision of parameter estimates, and decreases in the minimum objective function values were used for the model evaluation.

Results:
A 2-compartment model with an absorption lag and a combined error model adequately described the PK of clozapine. The implementation of disease progression with placebo and drug effects improved the model's ability to describe the time course of the PANSS scores. In the final PK/PD model, Weibull and maximum effect (Emax) models were selected as disease progression models for the placebo and drug effect models, respectively. The model evaluation results supported the adequacy of the final model.

Conclusions:
A clozapine PK/PD model based on clinical settings adequately described the PANSS time course in patients with SCZ. These findings may aid the development of treatment strategies for patients with SCZ.
Longitudinal associations of psychosocial stressors with menopausal symptoms and well-being among women in midlife
Authors: Faleschini Sabrina , Tiemeier Henning , Rifas-Shiman Sheryl L. , Rich-Edwards Janet , Joffe Hadine , Perng Wei , Shifren Jan , Chavarro Jorge E. , Hivert Marie-France , Oken Emily 
Published: September 2022

Abstract

Objective
We examined longitudinal associations of psychosocial stressors with menopausal symptoms and well-being of women in midlife in a longitudinal cohort.

Methods
This study is based on 682 women from Project Viva, a prospective cohort enrolled in 1999 to 2002 during pregnancy (median age = 33.3 y) and followed for almost two decades. In pregnancy, women self-reported psychosocial stressors (history of physical and sexual abuse and financial instability, from childhood to the current pregnancy). In 2017 to 2021 (median age, 51.6 y), they reported their menopausal symptoms (0‐44 point scale) and well-being (general health [good/fair/poor vs excellent/very good], generalized anxiety symptoms, and depressive symptoms [both—more than minimal levels vs none/minimal]). We performed multivariable and logistic regression models to examine associations of psychosocial stressors with outcomes, adjusting for covariates.

Results
History of physical abuse (reported by 37.3%) was associated with worse menopausal symptoms in the somatovegetative (odds ratio [OR], 0.46 points; 95% confidence interval [CI], 0.04-0.87 points) and psychological (OR, 0.52 points; 95% CI, 0.07-0.97 points) domains and with worse general health (OR, 1.73; 95% CI, 1.17-2.55) and greater depressive symptoms (OR, 1.74; 95% CI, 1.05-2.87). History of sexual abuse (7.7%) was associated with worse menopausal symptoms (OR, 2.81 points; 95% CI, 1.05-4.56) and worse general health (OR, 2.04; 95% CI, 1.04-4.03) but not with depressive symptoms. History of financial instability (10.8%) was associated with worse menopausal symptoms (1.92 points; 0.49 to 3.34), worse general health (OR, 2.16; 95% CI, 1.24-3.75), and greater depressive symptoms (OR, 2.68; 95% CI, 1.44-4.98). We observed no association between psychosocial stressors and generalized anxiety symptoms assessed at midlife.

Conclusions
Psychosocial stressors were associated with worse menopausal symptoms and well-being decades after initial report.
A New Treatment Paradigm
Authors: Kane John M. 
Published: September 2022

This continuing education supplement is jointly provided by Medical Education Resources and CMEology. The supplement is supported by an independent educational grant from Sunovion Pharmaceuticals Inc. It was edited and peer reviewed by the Journal of Clinical Psychopharmacology.
After reviewing the learning objectives and reading the supplement, please complete the Activity Evaluation/Credit Request form online at https://www.cmesurvey.site/TAAR1.

Abstract
All currently available antipsychotics work via essentially the same mechanism: by antagonizing the dopamine D2 receptor. However, schizophrenia is an extremely heterogeneous condition, and antipsychotics do not adequately control symptoms for all patients. Negative and cognitive symptoms are especially difficult to manage with existing medications. Therefore, antipsychotic agents with novel mechanisms of action are urgently needed. Recently, a phase 2 clinical trial and extension study demonstrated that, relative to placebo, the trace amine–associated receptor 1 (TAAR1) agonist ulotaront was effective at controlling the positive, negative, and cognitive symptoms of schizophrenia. In addition, ulotaront seems to lack the weight gain, metabolic issues, and extrapyramidal symptoms associated with traditional antipsychotics. This agent is currently undergoing multiple phase 3 trials for the treatment of schizophrenia. Another TAAR1 agonist, ralmitaront, is being investigated for the treatment of schizophrenia and schizoaffective disorders. Two phase 2 clinical trials are underway, evaluating ralmitaront both as a monotherapy and an add-on therapy to traditional antipsychotics. In this supplement, we review the biologic, preclinical, and clinical data available for TAAR1 agonists, so that if and when they are approved for the treatment of schizophrenia, psychiatry specialists will be ready to use them to optimize patient outcomes. We also briefly review other emerging therapies in late-stage development for the treatment of schizophrenia.